Introduction
Heart failure (HF) is a leading cause of morbidity and mortality worldwide, but, in the last decades, the development of treatments has improved the survival of chronic HF patients, mainly of those with reduced ejection fraction (HFrEF).
1,2 Moreover, the application of guideline recommendations is now widespread, and this appears to be among the causes of outcome improvement.
3 Data from population-based studies reported a decline in HF-related hospitalizations and mortality over the last two decades. However, no further improvement was reported in the most recent years. 4, 5 It is presently unknown whether and how the prognostic value of recognized predictors has changed over time. Among them, data derived from exercise evaluation, and specifically from cardiopulmonary exercise test (CPET), have gained a recognized pivotal role in HF prognosis both alone 6 -9 and in combination with non-CPET parameters.
10 -12 Among CPET parameters, oxygen uptake at peak exercise (peak VO 2 ) and the slope of the relationship between minute ventilation and carbon dioxide production (VE/VCO 2 slope) have been recognized and validated as tools to assess disease severity, to discriminate short-and long-term HF prognosis, and to select patients for heart transplantation (HTx).
13 -15 Indeed, since the pioneering classification by Weber and Janicki, 16 HF severity has been ranked using peak VO 2. Later, Mancini et al. 6 proposed a cut-off value of 14 mL/min/kg to identify poor prognosis and to select patients for HTx. This value was then reduced to 12 mL/min/kg in HF patients receiving beta-blocker treatment. 17, 18 Other authors suggested the existence of an 'undefined risk zone' and the need to combine peak VO 2 with other CPET-derived parameters to better assess prognosis. 7, 8, 19, 20 Thus, albeit extremely desirable, a single peak VO 2 cut-off value is unlikely to be clinically useful in the general HF population. Regardless, for HTx indication, peak VO 2 and 14 mL/min/kg have been used for many years. 13 Another point of uncertainty is the definition of high mortality risk, considering both the type of event and the duration of follow-up needed to assess the risk. Indeed, the used definition of high risk or poor outcome 6, 8, 10, 21, 22 is variable between different reports, vague, and often not even clearly defined. Differently, VE/VCO 2 slope has only more recently been proposed, 7, 9 and a slope value of 34 has been recognized to identify patients with poor prognosis despite differences in age and gender. 23 -25 As a matter of fact, an increasing risk has been associated with a high VE/VCO 2 slope value. 7, 11 The aim of this study was to assess whether and how the value of peak VO 2 and VE/VCO 2 slope as tools capable of stratifying HF prognosis has changed over the last 20 years.
Methods

Population and study procedures
We retrospectively analysed data from a cohort of 6083 patients with a history of HFrEF, consecutively enrolled and prospectively followed in 23 Italian HF centres participating in the Metabolic Exercise Cardiac Kidney Index (MECKI) score research group. 11 The MECKI score database is continuously updated both with new cases and with the follow-up of previously enrolled patients. The first patient for the present analysis was enrolled in January 1993 and the last one in December 2015, the latter to allow a follow-up > 2 years.
Inclusion criteria at enrolment were previously described in detail. 11 In brief, previous or present HF symptoms and former documentation of left ventricular ejection fraction (LVEF) < 40%, stable clinical condition, stable HF treatment for at least 3 months, and ability to perform a CPET were considered as main inclusion criteria. Exclusion criteria were: history of pulmonary embolism, moderate-to-severe aortic and mitral stenosis, pericardial disease, severe obstructive lung disease, exercise-induced angina and significant electrocardiographic alterations, or presence of any clinical co-morbidity interfering with exercise performance.
At enrolment, clinical history was recorded, and physical examination, laboratory analyses, electrocardiogram, transthoracic echocardiography, and CPET were performed and interpreted as previously described. 11 In the great majority of cases (95%), CPET was performed using a personalized ramp protocol on an electronically braked cycle ergometer or a modified Bruce protocol on a treadmill. Peak VO 2 data measured at treadmill were reduced by 10% to allow an appropriate comparison between the two different procedures. 11 Peak VO 2 was calculated as the 20 s average of the highest recorded VO 2 . Peak VO 2 % of the predicted value was calculated according to Hansen et al. 26 The VE/VCO 2 slope was calculated as the slope of the relationship using all breaths from 2 min after the onset of loaded pedalling to the respiratory compensation point. The anaerobic threshold was calculated by plotting VCO 2 vs. VO 2 on squared equal scales graph.
Data analysis and study endpoint
For the present analysis, we considered as study endpoint the occurrence of cardiovascular death, urgent HTx, defined as UNOS status 1, 27 or left ventricular assist device (LVAD) implantation.
To investigate the change in the prognostic value of peak VO 2 and VE/VCO 2 slope over time, we divided patients into four groups starting from the year of inclusion in the MECKI score database. . This grouping strategy creates groups of different sizes, but it was based on arbitrary criteria aimed firstly to separate patients enrolled before the year 2000, i.e. before a widespread knowledge of the first European guidelines on HF treatment, 28 and then in 5-year periods from 2001 to 2015. In a first step of the analysis, we compared the 10-year survival between the four groups, both using raw data and after correction for peak VO 2 and VE/VCO 2 slope as well as for major clinical and therapy variables that resulted different between groups, to exclude that patients with different HF severity had been enrolled over the years, thus affecting the behaviour of prognosis over time.
In a second step, in the same four groups, we analysed how the risk of the study outcome changed over time according to peak VO 2 (mL/min/kg) and VE/VCO 2 slope values, and we defined across the four groups of patients the peak VO 2 (mL/min/kg) and VE/VCO 2 slope cut-off values able to identify a risk of 10% and 20% of the study outcome.
Follow-up and data management
Procedures of data management were performed as previously described in detail.
11 In brief, follow-up was carried out according to the local HF programme, and it ended with the last clinical evaluation or with patients' death, urgent HTx, or LVAD implantation.
The present research protocol complies with the Declaration of Helsinki, and it was approved by the Ethics Committee of Centro Cardiologico Monzino, IRCCS (CE protocol no. R116/14-CCM127). The predicted 2-year cumulative risks of the composite event (cardiovascular mortality, urgent HTx, or LVAD implantation), associated with VO 2 and VE/VCO 2 slope values within each time range, were computed by Cox regression according to the formula: 1 − S 0 (t) exp(x ) , where S 0 (t) is the predicted baseline survival at time t, x is the value of VO 2 or VE/VCO 2 slope, and is the estimated Cox regression coefficient for VO 2 or VE/VCO 2 slope.
Statistical analysis
Using the plots derived from this analysis, we extrapolated the VO 2 and VE/VCO 2 slope values associated with a pre-specified 2-year event risk of 10% and 20%.
Results
A total of 6083 HFrEF patients (81% male, age 61 ± 13 years) were included in the present analysis ( Table 1) . At study enrolment, patients were in stable clinical conditions, and treatment was considered 'optimized' by the physicians in charge of the patients. Notably, the number of patients treated with ICD and CRT progressively increased, as well as the number of patients treated with beta-blockers. Interestingly, because a few patients (n = 130) were treated with both ACE inhibitors and angiotensin II receptor blockers (ARB), the number of subjects not receiving ACE inhibitors and ARB was similar between groups (3.6%, 8.6%, 8.8%, 10% in group 1, 2, 3, and 4, respectively), except for patients recruited in the early phase of enrolment, in whom, on the contrary, beta-blocker treatment was lower. Average LVEF was 33.2% ± 10.5, and it was between 40% and 49% in 1136 cases and ≥ 50 in 420 cases. Treadmill was used in 6% of cases. Mean peak VO 2 was 14.8 ± 4.9 mL/min/kg (56 ± 17% of predicted value), and mean VE/VCO 2 slope value was 32.8 ± 7.7. In 179 out of 6083 patients, VE/VCO 2 slope was not measured due to several reasons, including poor quality of data and erratic breathing. In 2796 (46%) patients, HFrEF aetiology was an ischaemic cardiomyopathy. Fifteen per cent of patients were in New York Heart Association (NYHA) class I, 57% in NYHA class II, 27% in NYHA class III, and 1% in NYHA class IV but able to perform a CPET. The median follow-up period was 3.32 years (IQR 1.58-5.54).
Patients enrolled in the years 1993-2000 (group 1) were younger, with a lower peak VO 2 % of the predicted value and LVEF ( Table 2) . As regards treatment, both ICD and CRT progressively increased as beta-blockers and mineralocorticoid receptor antagonists (MRA) did.
The median follow-up of group 1 was 5.04 years (IQR 20.3-10), and the event rate at 10 years was 82/1000 person-year; group 2 had a median follow-up of 7.24 years (IQR 3.60-10), and an event rate of 45/1000 person-year was observed at 10 years; the median follow-up of group 3 was 5.02 years (IQR 3.04-6.68), and the event rate at 10 years was 30/1000 person-year, and group 4 was followed for a median period of 1.76 years (IQR 0.90-2.81) with a 10-year event rate of 30/1000 person-year (P < 0.0001 between groups). Ten-year survival analysis showed significant differences between groups (log-rank < 0.001) ( Figure 1A) Figure 1B and 1C) , indicating a steady improvement over time independently of peak VO 2 and VE/VCO 2 slope. When data were normalized for clinical variables, such as peak VO 2 , VE/VCO 2 slope, Na + , kidney function by means of MDRD formula, and haemoglobin -all known to be independent survival predictors 11,12 -results were unchanged. However, when also treatment variables -which resulted significantly different between groups (such as ICD, CRT, ACE inhibitors, beta-blockers, aldosterone antagonists) -were added, Kaplan-Meier survival curves showed an unchanged trend, but statistical difference was observed only between group 1 and the other groups. Specifically, HRs were: HR 0.57, P < 0.001 group 2 vs. group 1; HR 0.49, P < 0.001 group 3 vs. group 1; HR 0.55, P < 0.001 group 4 vs. group 1; HR 0.87, P < 0.09 group 3 vs. group 2; HR 0.97 P < 0.8 group 4 vs. group 2; HR 0.86, P = 0.14 group 3 vs. group 4.
In the second step of the analysis, we considered the risk of the study outcome according to peak VO 2, and VE/VCO 2 slope values ( Figure 2) . Regarding peak VO 2 , we confirmed that the risk progressively increased along with the reduction of peak VO 2 , although with different curves in the four time periods, and we observed that a specific cut-off value of peak VO 2 was related to a progressive reduction of the risk (e.g. 10% and 20%) up to 2010. Inversely, regarding VE/VCO 2 slope, we similarly confirmed that the risk progressively increased along with the increase of the slope, and we observed that a specific cut-off value of VE/VCO 2 slope was related to a progressive reduction of the risk up to 2010. After 2010, the risk profile was unchanged both for VO 2 and VE/VCO 2 slope values.
We then identified the peak VO 2 and VE/VCO 2 slope cut-off values able to predict a 10% and 20% risk of events (combination of cardiovascular death, urgent HTx, and LVAD implantation) over time ( Table 3) . As expected, in the first three groups, peak VO 2 cut-off values progressively decreased, while VE/VCO 2 slope cut-off values progressively increased, both indicating a better prognosis for similar peak VO 2 and VE/VCO 2 slope values.
Discussion
In the present study, we retrospectively analyzed a typical HF population and its changes in prognosis over the last 20 years using Figure 1 Ten-year survival analysis, considering the occurrence of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation as study endpoint (A), corrected for oxygen uptake (VO 2 ) (B) and the slope of the relationship between minute ventilation and carbon dioxide production (VE/VCO 2 slope) (C).
the MECKI score research group database, a multicentre nationwide HFrEF database based on CPET analysis and continuously updated. The patients of the present analysis were enrolled in several Italian HF referral centres with similar behaviours in terms of therapeutic approach and follow-up management. We showed that HFrEF prognosis, assessed as the combined outcome of cardiovascular death, urgent HTx, and LVAD implantation, improved over time form 1993 up to 2010 without further changes later on, 5 and with no interaction of definite prognostic CPET parameters, such as peak VO 2 and VE/VCO 2 slope, when considered as potential confounding variables. We also confirmed that, regardless of when assessed but with different values, the risk progressively increases as peak VO 2 decreases or VE/VCO 2 slope value increases, respectively. In parallel, the cut-off values of peak VO 2 and VE/VCO 2 slope able to identify a 10% or 20% risk of the composite study outcome decreased and increased respectively up to 2010, with similar cut-off values observed over this time point. A similar hypothesis has been recently suggested by Levy and Dardas, 29 who showed a reduction of risk for the same peak VO 2 when comparing Cleveland Clinic and Columbia, University of Washington and Michigan patients 30, 31 vs. the more recently studied HF-ACTION and Brigham and Women's Hospital patients. Treatment of HFrEF has significantly changed over the last 20 years, and a progressively widespread use of HF guidelines, which has led to an improvement of patient management and follow-up, could be addressed as the main explanation of the survival improvement observed in the present study. Thus, the implementation of guidelines and the continuous update of HF pharmacological and device-based treatment observed in the last years are likely to be the main explanation for the increase and decrease, respectively, of the cut-off values of peak VO 2 and VE/VCO 2 slope indicating a risk of the study event of 10% and 20%. This is not the case for patients enrolled between 2011 and 2015, who showed a prognosis quite similar to that of patients enrolled between 2006 and 2010. This break in prognosis improvement can be attributed to the lack of further evolution in HFrEF treatment and management observed in the most recent years. Indeed, HF treatment in the clinical setting has significantly changed with the first European HF guidelines published in 1995 34 and 1997. 28 These guidelines, applied progressively and widely in Italy, legitimated and recommended the use ACE inhibitors in all stages of symptomatic HF due to systolic cardiac dysfunction, irrespective of the presence or absence of signs of volume overload with still some concerns on the use of beta-blockers and potassium-sparing diuretics. Then, in 2001, 35 the use of beta-blockers and MRA in HF was definitely A B Figure 2 Graphical analysis of risk of the study outcome according to (A) peak oxygen uptake (VO 2 ) and (B) the slope of the relationship between minute ventilation and carbon dioxide production (VE/VCO 2 slope). Risk was the composite of cardiovascular death, urgent heart transplantation, and left ventricular assist device implantation.
cleared. In 2005, 36 the use of ICD was included with a class of recommendation IIa, level of evidence B, and in 2008, 37 the recommendation on CRT implantation to reduce morbidity and mortality appeared. In 2012, guidelines were published 38 with no new drugs or new indications for devices. Thus, the lack of new treatment options after 2008, with the exception of ivabradine, which, however, is not yet widely used, might explain the similar risk level in patients enrolled after 2010 in the present study. Indeed, when the analysis was normalized for major clinical and therapeutic variables, which resulted significantly different between groups, survival differences between groups significantly decreased. It is conceivable, however, that the widespread use of any new treatment option 39 will likely further improve survival and possibly risk cut-off values.
Regarding the identification of specific cut-off values to define HF prognosis over time, several reports 6 -8,17-20 in the last years proposed 'magic numbers' for peak VO 2 and VE/VCO 2 slope to define high-risk patients and to select them for HTx. 2, 13 However, in the present study, we observed, in a specific HFrEF population, that peak VO 2 and VE/VCO 2 slope cut-off values related to a definite risk significantly changed over time with a progressive reduction of peak VO 2 This study has a few limitations. First of all, the evaluation of patients and the assessment of the prognostic role of peak VO 2 and VE/VCO 2 slope were only done once at study run-in. In other words, we did not evaluate any possible therapeutic upgrade during the follow-up, as well as we did not consider the effects of repeated CPET on prognosis. This may also contribute to explain the lack of clinical improvement observed in patients recruited between 2005 and 2010 vs. those recruited between 2010 and 2015. Indeed, albeit minor (Table 2) , a further upgrade of treatment was observed between the two patient groups. Secondly, the present population was treated and followed in top HF units most often located in major towns. Therefore, we do not know whether similar results are obtained in more peripheral centres or in patients followed in treatment units not so sophisticated. Thirdly, we evaluated the prognostic role of two selected parameters, peak VO 2 and VE/VCO 2 slope. We do not know, although it is likely, whether the same time-dependent prognostic threshold changes apply to other parameters used for prognosis identification either considered as single measurements or as a combination of parameters in scores. Fourthly, the study endpoint was the composite of cardiovascular death and urgent HTx or LVAD. It is acknowledged that both HTx and LVAD are, albeit urgent, associated with medical decision, which has, by definition, an arbitrary component. However, similar results were obtained using total mortality as a study endpoint (data not shown). Fifthly, patients of group 4, recruited between 2001 and 2005, had by necessity a shorter follow-up than patients enrolled earlier. Accordingly, we do not know whether the same positive survival trend will be maintained in the long period. Lastly, our population is predominantly made up of male patients, thus our results are mainly applicable to this setting. However, in our database, patients were consecutively enrolled, and no sex-based selection was made at study enrolment. Therefore, this population mirrors the sex distribution of Italian HF outpatients, at least of those undergoing CPET for clinical reasons, possibly as the result of a gender-specific medical malpractice.
In conclusion, we showed that HFrEF patients' survival improved over time, and that peak VO 2 and VE/VCO 2 slope cut-off values able to identify a 10% or 20% risk progressively decreased and increased, respectively. Consequently, the prognostic role of peak VO 2 and VE/VCO 2 slope must be analysed always referring to a specific HF population, and their values need to be updated. This likely applies also to scores that include peak VO 2 and VE/VCO 2 slope, such as the MECKI score. Finally, our findings may lead to re-discuss indication and cost-effectiveness of several clinical interventions such as HTx, LVAD, CRT, or even some expensive pharmacological tools. Conflict of interest: none declared.
